PLEASANTON, Calif., June 22, 2018 (GLOBE NEWSWIRE) -- Natus Medical Incorporated (NASDAQ: BABY ) today announced that, based on a preliminary vote count provided by its proxy solicitor following the Company’s 2018 Annual Meeting of Stockholders, Natus stockholders have voted to elect Voce Capital’s nominees Joshua H. Levine and Lisa Wipperman Heine to the Natus Board of Directors. The preliminary count also indicated that stockholders voted to reject Voce’s proposal to remove Natus’ Chairman of the Board, Robert Gunst.
Natus Medical issued the following statement:
We appreciate the consideration and support of our stockholders, as well as the valuable insights they have offered our Board and management team. We look forward to working collaboratively with Joshua Levine and Lisa Wipperman Heine. We will move ahead expeditiously to confirm the vote so that the Natus Board can focus on enhancing value for stockholders.
We would like to express our sincere gratitude to Doris Engibous and William Moore, one of our founders, for their dedicated service to Natus and its Board. We wish them all the best in their future endeavors.
The Company expects to announce final results of the matters presented for approval at the annual meeting following the official certification of the results by American Election Services, the independent inspector of elections, within the next few business days. Assuming the final results confirm the preliminary estimates, Mr. Levine and Ms. Wipperman Heine will join Robert A. Gunst, James B. Hawkins, Kenneth E. Ludlum and Barbara R. Paul on the Natus Board of Directors.
The results of the vote announced today are considered preliminary until final results are tabulated and certified. Final results will be reported on a Form 8-K that will be filed with the U.S. Securities and Exchange Commission, at which time they will become available on https://investor.natus.com/ and www.sec.gov .
About Natus Medical Incorporated
Natus is a leading provider of healthcare products and services used for the screening, detection, treatment, monitoring and tracking of common medical ailments in newborn care, hearing impairment, neurological dysfunction, neurosurgery, epilepsy, sleep disorders, and balance and mobility disorders.
Additional information about Natus Medical can be found at www.natus.com .
Forward Looking Statements
This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, particularly statements regarding the expected results of the annual meeting. Forward-looking statements are only predictions and the actual events or results may differ materially. Our future results could differ materially due to a number of factors Natus disclaims any obligation to update information contained in any forward looking statement.
More information about potential risk factors that could affect the business and financial results of Natus is included in Natus' annual report on Form 10-K for the year ended December 31, 2017 and its subsequent quarterly reports on Form 10-Q and in other reports filed from time to time by Natus with the U.S. Securities and Exchange Commission.
Contacts
Natus Medical Incorporated Jonathan A. Kennedy Executive Vice President and Chief Financial Officer 925-223-6700 InvestorRelations@Natus.com
Joele Frank, Wilkinson Brimmer Katcher Adam Pollack 212-355-4449
